Page last updated: 2024-08-24

lisofylline and Hematologic Malignancies

lisofylline has been researched along with Hematologic Malignancies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andrews, F; Bianco, JA; Dahlberg, S; Jansen, J; Karanes, C; Kirkhart, B; Liesveld, J; List, AF; Litzow, M; Maziarz, R; Schuster, M; Singer, JW; Stiff, P; Wolff, S1

Trials

1 trial(s) available for lisofylline and Hematologic Malignancies

ArticleYear
A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    Bone marrow transplantation, 2000, Volume: 25, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Behavior Therapy; Bone Marrow Transplantation; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Evaluation Studies as Topic; Female; Graft vs Host Disease; Hematologic Neoplasms; HLA Antigens; Humans; Infections; Male; Middle Aged; Nuclear Family; Pentoxifylline; Placebos; Recurrence; Survival Rate; Time Factors; Tissue Donors; Transplantation, Homologous; Whole-Body Irradiation

2000